Navigation Links
Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
Date:2/2/2009

TSX Venture: QPT

EDMONTON, Feb. 2 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, announces that it has entered into an agreement with Loewen, Ondaatje, McCutcheon Limited ("LOM") to provide financial advisory services in connection with various business development opportunities.

"The current capital market conditions have provided us with alternative strategic opportunities including mergers and acquisitions, strategic partnerships and monetizing certain capital assets," said Dr. Madiyalakan, Chief Executive Officer for Quest. "In order to position the Company for future growth and to increase shareholder value, we are evaluating these alternatives with the help of LOM." In addition, Quest would also like to leverage the valuable clinical and preclinical data it has generated from its proprietary SonoLight Technology, as well as the continuing support from its current shareholders.

Quest also announces the grant of 300,000 stock options to its three independent board members at an exercise price of $0.15. All allocations will be subject to approval of the TSX Venture Exchange.

Quest has four product candidates in development based on its proprietary SonoLight Technology. SL017, for hair removal, is currently in a Phase II, 110-patient clinical trial. SL017, for the treatment of actinic keratosis, has been shown to be safe and well tolerated in a Phase 1 dose-escalation clinical trial. SL017, for the treatment of acne, has completed evaluation in a Phase 1 clinical trial. SL052, which is being developed to treat prostate cancer, has completed preclinical studies.

About Quest PharmaTech Inc. Quest is a publicly traded, Alberta-based pharmaceutical company committed to the development and commercialization of new pharmaceutical products. It i
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... WASHINGTON , Aug. 5, 2015 ... Energy and Commerce Committee members Reps. Joe Barton ... well as a delegation of 33 House members, for ... Slavitt , acting administrator for the Centers for Medicare ... biosimilar reimbursement in the CMS,s 2016 Medicare Physician Fee ...
(Date:8/5/2015)... GenomeDx Biosciences announced that it will present at the Wedbush ... 12, in New York . Dave Matthews ... company,s Decipher ®  test and an overview of the Company,s ... Decipher ®  Prostate Cancer Classifier is a highly validated and ... risk prostate cancer. The test is the only genomic test ...
(Date:8/5/2015)... Gaithersburg, MD (PRWEB) , ... August 05, 2015 ... ... reagents for the life sciences, announces the launch of an updated corporate identity, ... acquired by Molecular Transfer, Inc. (MTI) in 2009. The company moved into a ...
(Date:8/4/2015)... 4, 2015 According to ... titled, "World Cardiac Biomarker - Market Opportunities, and ... generate the revenue of $2,085.9 million by 2020, ... 2020. Cardiac Troponins (T, I) would continue to ... to high sensitivity and specificity.      ...
Breaking Biology Technology:Biosimilars Forum Applauds Reps. Barton, Eshoo for Leadership on Proposed Medicare Rule on Biosimilar Coding 2Biosimilars Forum Applauds Reps. Barton, Eshoo for Leadership on Proposed Medicare Rule on Biosimilar Coding 3GenomeDx Biosciences to Present at 2015 Wedbush PacGrow Healthcare Conference 2GenomeDx Biosciences to Present at 2015 Wedbush PacGrow Healthcare Conference 3MTI-GlobalStem Announces Updated Company Identity and Website 2MTI-GlobalStem Announces Updated Company Identity and Website 3Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 3Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 4Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 5
... Revenue; Gross Margin Increase ... Continues; Net Losses Decline, IRVINE, ... device company focused on the development of,minimally invasive technologies for ... sales and procedures and,continued expense reductions in the three months ...
... SAN DIEGO, May 1 Vical Incorporated (Nasdaq:,VICL) today ... quarter ended March 31, 2008, before the opening of ... and webcast to discuss the,financial results and provide a ... The call is open on a listen-only basis to ...
... PRINCETON, N.J., May 1 Orchid Cellmark Inc.,(Nasdaq: ... testing,services, will release its first quarter 2008 financial results ... and is hosting a,conference call and webcast to discuss ... Management will discuss financial results for the first quarter,2008 ...
Cached Biology Technology:Endocare Reports 2008 First Quarter Financial Results 2Endocare Reports 2008 First Quarter Financial Results 3Endocare Reports 2008 First Quarter Financial Results 4Endocare Reports 2008 First Quarter Financial Results 5Endocare Reports 2008 First Quarter Financial Results 6Endocare Reports 2008 First Quarter Financial Results 7Endocare Reports 2008 First Quarter Financial Results 8Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results 2Orchid Cellmark to Announce First Quarter 2008 Financial Results on May 8, 2008 2
(Date:7/21/2015)... 21, 2015 Today, ZTE announced its Android ... well as expected revenues in 2015 that relate to sales of ... guidance of approximately 2,200 MSEK for 2015. Jörgen Lantto, ... smartphone manufacturer in China and we are ... 5 for Axon , its ...
(Date:7/20/2015)... DENVER , July 20, 2015  Acuity ... Mobility Report: The Convergence of Commerce and Privacy" ... billion mobile biometric apps will be downloaded to ... users. The mobile biometrics market is projected to ... app revenue during the seven-year forecast period.    ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 30, 2015 after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... can build its way to a more energy efficient future ... by improving the rules regulating these structures, according to ... Laboratory. PNNL scientists at the Joint Global Change Research ... Park, Md., have created a unique model that projects how ...
... Like little factories, cells metabolize raw materials and ... of this ability, using microorganisms to produce pharmaceuticals ... scale and create new types of chemicals, biotechnologists ... certain genes in the cell. But such metabolic ...
... have identified how a single gene in honey bees separates ... from Michigan State University and Wayne State University unraveled the ... issue of Biology Letters . The gene, which is ... in the evolution of bees, ability to carry pollen. ...
Cached Biology News:Modeling buildings by the millions: Building codes in China tested for energy savings 2Modeling buildings by the millions: Building codes in China tested for energy savings 3Modeling buildings by the millions: Building codes in China tested for energy savings 4A digital test for toxic genes 2A digital test for toxic genes 3Single gene separates queen from workers 2
G-protein coupled purinergic receptor P2Y8...
Acid phosphatase (Potato). Monospecific by IEP. Some cross reactivity between Acid phosphatases of other species may occur....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
... to Yersinia pestis This antibody ... . Immunogen: Purified ... vaccine strain EV76. ... F1 capsular antigen. There is no ...
Biology Products: